Results 101 to 110 of about 530,239 (305)

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

open access: yesArthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández   +10 more
wiley   +1 more source

Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. [PDF]

open access: yes, 2014
The high mortality of melanoma is caused by rapid spread of cancer cells, which occurs unusually early in tumour evolution. Unlike most solid tumours, thickness rather than cytological markers or differentiation is the best guide to metastatic potential.
Gabriela Kalna (192504)   +76 more
core   +1 more source

13 | Spatial contexture of tertiary lymphoid structures as a predictor of recurrence in early-stage melanoma

open access: yesDermatology Reports
Background: Tertiary Lymphoid Structures (TLS) are organized aggregates of immune cells that form in non-lymphoid tissues in response to chronic inflammation, including cancer.
Italian Melanoma Intergroup
doaj   +1 more source

Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation–associated protein 5 (MDA5) antibody–associated dermatomyositis (DM). Methods Thirty patients with MDA5 antibody–associated DM were identified in a single‐center longitudinal cohort of 352
Jenice X. Cheah   +8 more
wiley   +1 more source

Progression to invasive melanoma frommalignant melanoma in situ, lentigo maligna type [PDF]

open access: yes, 2017
We have previously hypothesized that lesions that have been termed lentigo maligna can be divided into 2 categories: 1 represents a pigmented lesion that is a precursor to melanoma, and the other melanoma in situ.
Tannous, Zeina   +4 more
core   +1 more source

Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma

open access: yesnpj Precision Oncology
Tumour mutation burden (TMB) is a promising biomarker in predicting immunotherapy response, yet its reproducibility across target panels needs to be established. This study assessed the reproducibility of TMB estimates in melanoma using TruSight Oncology
Yizhe Mao   +16 more
doaj   +1 more source

30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial)

open access: yesDermatology Reports
Background: Nevoid Basal Cell Carcinoma Syndrome (NBCCS), or Gorlin syndrome, is a rare genetic condition characterized by multiple basal cell carcinomas (BCCs). Some sporadic BCC patients present multiple lesions, classified as difficult-to-treat (EADO
Italian Melanoma Intergroup
doaj   +1 more source

Melanoma

open access: yesThe Oncologist, 2001
Abstract The presentations at the American Society of Clinical Oncology 2001 meeting reported or updated the results of phase I, II, and III randomized trials and also reported important meta-analyses and retrospective studies impacting on the management of patients with melanoma.
openaire   +2 more sources

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

open access: yesArthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino   +9 more
wiley   +1 more source

32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy

open access: yesDermatology Reports
Background: Real world data are needed to optimize the use of Tebentafusp, the first agent improving the overall survival in metastatic uveal melanoma (mUM) patients even if progressive disease (PD) is the best response. Methods: Baseline clinical data,
Italian Melanoma Intergroup
doaj   +1 more source

Home - About - Disclaimer - Privacy